Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases

Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is uncommon with an estimated all time incidence around 1% worldwide. Moreover, a case of gefitinib ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Yon Ju, Chun, Eun Mi, Lee, Soon Nam, Shim, Sung Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Radiology 2014
Materias:
Thoracic Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955799/
https://www.ncbi.nlm.nih.gov/pubmed/24642811
http://dx.doi.org/10.3348/kjr.2014.15.2.300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955799/
https://www.ncbi.nlm.nih.gov/pubmed/24642811
http://dx.doi.org/10.3348/kjr.2014.15.2.300

Ejemplares similares